Key facts
- This page summarizes RA CAPITAL MANAGEMENT, L.P.'s Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Dec 2024, 16:28.
RA CAPITAL MANAGEMENT, L.P. - 09 Dec 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- FDMT
- Reported as of
- 09 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2024, 16:28:28 UTC
- Prior SEC filing
- 29 Nov 2024
- Next SEC filing
- 30 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RA CAPITAL MANAGEMENT, L.P. filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 10 Dec 2024.
Change
- Previous filing in this sequence was filed on 29 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FDMT
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- -535,000
- Change %
- -10%
- Price
- $0.000000
- Shares after
- 4,563,211
- Date
- 09 Dec 2024
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FDMT
transaction
Derivative
Pre-Funded Warrants (Right to Buy)
Other
- Transaction value
- Shares
- +535,000
- Change %
- +17%
- Price
- Shares after
- 3,610,000
- Date
- 09 Dec 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 535,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
RA CAPITAL MANAGEMENT, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
On December 9, 2024, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 535,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 535,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share.
Footnote F2
Held directly by the Fund.
Footnote F3
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
Footnote F4
The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.